Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Notes Payables (2016 - 2025)

Jaguar Health (JAGX) has disclosed Notes Payables for 11 consecutive years, with $23.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Notes Payables rose 101.17% to $23.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $23.1 million, a 101.17% increase, with the full-year FY2024 number at $12.0 million, up 147.34% from a year prior.
  • Notes Payables was $23.1 million for Q3 2025 at Jaguar Health, up from $18.6 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $23.1 million in Q3 2025 to a low of $1.1 million in Q2 2021.
  • A 5-year average of $10.2 million and a median of $11.1 million in 2024 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: tumbled 87.22% in 2021, then skyrocketed 594.59% in 2022.
  • Jaguar Health's Notes Payables stood at $3.2 million in 2021, then skyrocketed by 398.84% to $15.9 million in 2022, then plummeted by 69.36% to $4.9 million in 2023, then surged by 147.34% to $12.0 million in 2024, then soared by 91.96% to $23.1 million in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Notes Payables are $23.1 million (Q3 2025), $18.6 million (Q2 2025), and $18.6 million (Q1 2025).